Trials / Completed
CompletedNCT03273023
PROMUS PREMIER™ China Post-Approval Study
Post-Approval Study of the PROMUS PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,059 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compile real-world clinical outcome data for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System (Promus PREMIERTM Stent System) in routine clinical practice in China.
Detailed description
Each site will be allowed to enroll up to a maximum of 300 subjects. The scheduled follow up will occur at 30 days, 6 months, 12 months and then annually through 5 years post stent implant, for all enrolled subjects. Follow-up will be conducted via telephone contact or clinic visit
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System | Promus PREMIERTM Stent System |
Timeline
- Start date
- 2018-01-11
- Primary completion
- 2020-12-28
- Completion
- 2025-10-03
- First posted
- 2017-09-06
- Last updated
- 2026-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03273023. Inclusion in this directory is not an endorsement.